Free Newsletter
Researchers engineer a one-punch rabies vaccine
A team of virologists at Thomas Jefferson University in Philadelphia have genetically engineered a new rabies vaccine that appears to work after a single jab.
Currently anyone bitten by a rabid animal is required to undergo a series of painful vaccinations to stop the deadly virus. But the researchers took the virus and focused on a protein that triggers a powerful immune system response. They inserted several copies of the gene encoding the protein into the viral genome, according to Nature, and eliminated toxicity by altering two amino acids. The team found that the new vaccine eliminated the rabies virus from mice after a single shot.
"When you express a lot of glycoprotein, it makes it a better target because they're the target for the immune system," says co-author Craig Hooper, also at Thomas Jefferson. "But it's also more toxic. For the immune system that's a good thing: If the first cells you infect are going to die, that means you bump up immune response very quickly, so you prevent the virus from spreading."
If they're right and the same approach works in humans, the researchers will resolve one of the biggest problems associated with treating rabies victims. Because multiple injections are required, the vaccination schedule can be a big hurdle for people living in communities far from health clinics. More than 99 percent of the 55,000 people killed each year by rabies live in developing countries.
- read the article from Nature
Related Article:
Biologist calls for campaign to stop rabies
Comments
I don't think your comment "Currently anyone bitten by a rabid animal is required to undergo a series of painful vaccinations to stop the deadly virus" is correct.
I have had the primary series, and it was not painful at all - it was much better than tetanus or pneumonia vaccinations.
What is probably painful is the infusion of immune globulin after a bite. That's not needed if you have already received the vaccination.
I wonder if the new vaccine protects against european bat lyssavirus infections. There was a posted at the ICIED a few years back that indicated that the current vaccine wasn't always effective.
Post new comment
Paid Research Reports
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
- Seasonal Influenza Vaccines Market Forecast
- Generics Series: Authorized Generics Analysis
- Pricing and Reimbursement: Innovative Risk-Sharing Strategies



